0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Idelalisib is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): • who have received at least one prior therapy, or • as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2014-09-18
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No